PMGC Holdings Completes Acquisition of SVM Machining for $2.45M Plus $1.25M Earnout
ELAB sits 16% above its 52-week low of $1.52.
Summary
PMGC Holdings Inc. has completed the acquisition of SVM Machining, Inc. for a fixed price of $2.45 million, with an additional earnout potential of $1.25 million, significantly expanding its precision manufacturing footprint.
Key Events · M&A and Partnerships · ELAB
-
Acquisition of SVM Machining, Inc. Completed
PMGC Holdings Inc. finalized the acquisition of 100% of SVM Machining, Inc., a California-based precision CNC machining and manufacturing services company, on February 2, 2026.
-
Substantial Purchase Price
The aggregate purchase price was $2,449,148.08, consisting of $2,000,000 in cash at closing, a $250,000 indemnification holdback, a $130,000 cash balance, and a $69,148.08 working capital adjustment.
-
Contingent Earnout Consideration
Additional earnout payments of up to $1,250,000 are possible, contingent on SVM Machining achieving specific revenue targets through December 31, 2027.
-
Strategic Expansion in Precision Manufacturing
This acquisition is PMGC's third CNC machine shop purchase, furthering its strategy to build a multi-site machining platform. SVM Machining reported $3,042,701 in revenue for the fiscal year ended December 31, 2024.
Analysis · ELAB · Life Sciences
PMGC Holdings Inc. has completed a highly significant acquisition of SVM Machining, Inc., a precision CNC machining company. The fixed purchase price of approximately $2.45 million, coupled with a potential earnout of up to $1.25 million, represents a substantial transaction relative to PMGC's current market capitalization. This acquisition is strategically important as it marks PMGC's third CNC machine shop purchase, expanding its presence in the precision manufacturing sector. The target company, SVM Machining, reported revenues exceeding PMGC's market cap in the last fiscal year, indicating a potentially transformative impact on PMGC's operational scale. The deal structure, including a cash component, indemnification holdback, and performance-based earnouts, aims to align seller incentives with future growth. This follows a series of recent capital raises by PMGC, suggesting a concerted effort to fund strategic expansion.
At the time of this filing, ELAB was trading at $1.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $1.52 to $189.14. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.